Cargando…
Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471128/ http://dx.doi.org/10.1192/j.eurpsy.2021.895 |
_version_ | 1784788999216300032 |
---|---|
author | Galanopoulos, A. Tsiolka, E. Ntounas, P. Mpelimpasakis, D. Karakoutas, D. Sidiropoulos, N. Mpougiouklis, I. Kyziridis, K. Papalexi, E. |
author_facet | Galanopoulos, A. Tsiolka, E. Ntounas, P. Mpelimpasakis, D. Karakoutas, D. Sidiropoulos, N. Mpougiouklis, I. Kyziridis, K. Papalexi, E. |
author_sort | Galanopoulos, A. |
collection | PubMed |
description | INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015). OBJECTIVES: The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece. METHODS: In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses. RESULTS: 336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons). CONCLUSIONS: MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales. CONFLICT OF INTEREST: A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas. |
format | Online Article Text |
id | pubmed-9471128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94711282022-09-29 Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation Galanopoulos, A. Tsiolka, E. Ntounas, P. Mpelimpasakis, D. Karakoutas, D. Sidiropoulos, N. Mpougiouklis, I. Kyziridis, K. Papalexi, E. Eur Psychiatry Abstract INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015). OBJECTIVES: The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece. METHODS: In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses. RESULTS: 336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons). CONCLUSIONS: MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales. CONFLICT OF INTEREST: A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas. Cambridge University Press 2021-08-13 /pmc/articles/PMC9471128/ http://dx.doi.org/10.1192/j.eurpsy.2021.895 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Galanopoulos, A. Tsiolka, E. Ntounas, P. Mpelimpasakis, D. Karakoutas, D. Sidiropoulos, N. Mpougiouklis, I. Kyziridis, K. Papalexi, E. Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
title | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
title_full | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
title_fullStr | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
title_full_unstemmed | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
title_short | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
title_sort | improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: a patient-rated evaluation |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471128/ http://dx.doi.org/10.1192/j.eurpsy.2021.895 |
work_keys_str_mv | AT galanopoulosa improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT tsiolkae improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT ntounasp improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT mpelimpasakisd improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT karakoutasd improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT sidiropoulosn improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT mpougiouklisi improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT kyziridisk improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT papalexie improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation |